Clinical Trials
15 trialsNCT02568267 2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02655016 2026-03-10
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Tesaro, Inc.
Phase 3 Active not recruiting
NCT05116189 2026-03-09
KEYNOTE-B96
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT01844986 2025-12-10
SOLO-1
AstraZeneca
Phase 3 Active not recruiting
NCT01874353 2025-08-03
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
AstraZeneca
Phase 3 Active not recruiting
NCT05257408 2025-04-16
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Corcept Therapeutics
Phase 3 Active not recruiting
NCT00753545 2025-02-03
Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer
AstraZeneca
Phase 2 Completed
NCT03737643 2025-01-29
DUO-O
AstraZeneca
Phase 3 Active not recruiting
NCT04625270 2025-01-29
RAMP 201
Verastem, Inc.
Phase 2 Active not recruiting
NCT00716976 2023-11-09
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
Children's Oncology Group
Phase 3 Completed
NCT01968213 2023-06-09
ARIEL3
pharmaand GmbH
Phase 3 Completed
NCT02354586 2022-09-15
QUADRA
Tesaro, Inc.
Phase 2 Completed
NCT03180307 2022-02-04
OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
On Target Laboratories, LLC
Phase 3 Completed
NCT00262847 2019-07-23
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 3 Completed